ArticleFrontiers in medicine2026
Implementation of third-generation digital PCR for non-invasive prenatal diagnosis of sickle cell disease and early detection. Pilot study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sickle cell disease (SCD) is one of the most prevalent autosomal recessive conditions worldwide, affecting more than 600,000 newborns annually. Despite advances in treatment, it remains a chronic condition requiring lifelong management. Allogeneic transplantation and gene therapy are currently the only curative options when applicable and available. We present the results of a pilot study evaluating the use of digital PCR (dPCR) for non-invasive prenatal diagnosis (NIPD), a minimally invasive approach for SCD, based on relative pathogenic variant dosage (RMD, Relative Mutation Dosage) analysis in maternal plasma. Nine pregnant women carrying the pathogenic variant (βA/βS) were included. RMD values ranged from 0.436 to 0.501 (mean: 0.475) in cases with heterozygous fetuses and from 0.377 to 0.431 (mean: 0.397) in cases with wild-type fetuses. Z-score classification correctly identified fetal genotype in all conclusive cases (8/9), with one inconclusive result. Results were confirmed postnatally with 100% concordance in classified cases. These findings support the feasibility of dPCR-based NIPD for SCD as a minimally invasive approach. However, further validation in larger cohorts and with comprehensive quality control parameters is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.